New York City-based Stye treatment medications will soon be available for the treatment of stye, a rare condition caused by an infection of the skin and mucosa.
Stye is caused by the fungus Borrelia burgdorferi, which has been present in the environment for decades.
Its symptoms include blistering, fever, and skin irritation.
The new Stye medication will be offered as a combination of two different drugs, one for the skin, the other for the mucosa, a drug company representative told Ars Technia.
The two drugs will be administered in the same way, with the skin drug being given to people with stye symptoms while the mucosal drug will be given to those who are otherwise healthy.
According to the FDA, stye is a life-threatening disease, so the company’s plan to develop Stye will help the company avoid the stigma associated with the condition, which affects 1.3 million Americans, including some in the US military.
In addition to its new Stay drug, Stye also plans to start selling a new treatment pill in November that will treat the fungus’s effects in people who have been on the medication for up to six months.
The FDA has not yet approved the new Stee drug for use in the United States, but the company expects to soon.
Stays in the works for the drug companies also include a new drug to treat the symptoms of stything in children.
This drug is also being developed in collaboration with Stye.
According the FDA’s statement, the new drugs will “offer patients a new way to address stye’s debilitating effects, while also improving the patient’s overall quality of life.”
